Brief: Appili Therapeutics Announces Issuance Of Patent For ATI-1701 Biodefense Vaccine Candidate And Provides Update On Bridge Loan
15/12/2023 13:01
Dec 15 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES ISSUANCE OF PATENT FOR
ATI-1701
BIODEFENSE VACCINE CANDIDATE TO PROTECT AGAINST TULAREMIA AND
PROVIDES UPDATE ON BRIDGE LOAN
* APPILI THERAPEUTICS INC - PRE-IND MEETING WITH FDA GRANTED
TO
DISCUSS ATI-1701'S REGULATORY, CMC, TOXICOLOGY, AND PHASE 1
STRATEGIES
* APPILI THERAPEUTICS INC: PATENT COVERAGE PROVIDES
ATI-1701
BIODEFENSE VACCINE DRUG MARKET EXCLUSIVITY THROUGH AT LEAST 2039
* APPILI THERAPEUTICS INC: EXPECTS ATI-1701 CMO TO
SUCCESSFULLY
PRODUCE ENGINEERING BATCHES AND GMP BATCHES IN 2024
Source text for Eikon: ID:nBwc25ZD0a
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez